Aspen Neuroscience

autologous iPSC, neuron replacement, advanced genomics

replacementreplacingcell therapy

aspenneuroscience.com·San Diego, California, United States·Founded 2018·Series C Plus·$454M total funding

01Overview 02People 03Projects 04Concepts 05Patents 06Public records 07Belief evolution

Plate C · C-CG0Z

Projects

Autologous iPSC-derived neuron replacement platform

phase 1

platform · medium · Thu Nov 20 2025 00:00:00 GMT+0000 (Coordinated Universal Time)

Enable scalable personalized cell replacement therapies for Parkinson’s disease and other high-unmet-need CNS disorders using patients’ own cells.

Patient-specific iPSC-derived neuron manufacturing platform supported by machine learning, advanced genomics, and manufacturing automation.

Series C financing announced to accelerate personalized cell therapy programs.

ANPD001

phase 1

drug program · high · Tue Jan 23 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

Develop a personalized dopaminergic neuronal precursor cell replacement therapy for Parkinson’s disease by replacing dopamine-producing cells in the brain using cells manufactured from each participant’s own previously collected cells.

Autologous iPSC-derived cell therapy; patient cells are manufactured into ANPD001 cells intended to mature into dopamine-producing neurons and are injected into the brain in a Phase 1/2a clinical trial.

Phase 1/2a study of ANPD001 in Parkinson Disease listed on ClinicalTrials.gov.

Loading

Loading section...

0-100 chain-logic scale · 15 dimensions · scored on public evidence